(CNN) – The Johnson & Johnson vaccine against covid-19 complied with the requirements for the authorization of emergency use, following an analysis published this morning by the Food and Drug Administration of EE.UU. (FDA).
Johnson & Johnson vaccine efficacy against covid-19 moderate to severe / critical in all geographic areas exceeds 66.9% less than 14 days after single dose evacuation and 66.1% less than 28 days after the evacuation, following a new analysis intended to inform the FDA’s Assessment Committee for Vacancies and Biological Products.
MIRA: Pfizer, Moderna y Johnson and Johnson compromise a 240 million vacancy factory against covid-19 for EE.UU. for March fines
“We do not identify specific security concerns in the subgroup analysis by age, race, ethnicity, medical comorbidities or prevalence of SARS-CoV-2 infection,” he said.
In an informative document, the FDA stated that it had revised the vacancy data and determined that it was “consistent with the recommendations established in the Guidance of Emergency Use of Vacancies to Prevent the FDA COVID-19”.
An independent group of assessors from the FDA, the Committee for the Evaluation of Vacancies and Biological Products, considers the documents and has a recommendation on whether to authorize the vaccination against covid-19. The committee meets the quarters.
MIRA: In which countries did he evacuate more in South America? The map of advance, nation by nation